Also known as: ChAdOx1 nCoV-19 COVID-19 Vaccine AstraZeneca AZD1222
SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is the active ingredient of these drugs:
Austria France Ireland Lithuania Netherlands